Samsung Biologics Wins End-to-End Big Pharma Deals
Samsung Biologics (207940.KS) will handle contract manufacturing (CMO) of “zumilokibart,” a new drug candidate developed by global pharmaceutical…
#EuropeSays #Korea #KR #SamsungBiologics #AbbVie #Apogeeacquisition #CDMObusiness #CMOcontract #EliLillyclinicaltrial #Samsung #zumilokibart
https://www.europesays.com/korea/118722/